NCT00165789View on ClinicalTrials.gov

A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

February 28, 2006

Study Completion Date

September 30, 2006

Conditions
Parkinson's Disease
Interventions
DRUG

E2007

Trial Locations (10)

27607

Inc., Raleigh

33445

Brain Matters Research, Delray Beach

33486

Inc., Boca Raton

33701

Suncoast Neuroscience Associates, St. Petersburg

48034

Raleigh Neurology Associates, Southfield

72205

Clinical Trials Incorporated, Little Rock

79410

The Clinical Neuroscience Center, Lubbock

93030

UMDNJ - Robert Wood Johnson Medical School, Oxnard

06510

Parkinson's Disease and Movement Disorders Center of Boca Raton, New Haven

08854

Agape Medical Research Center, Piscataway

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT00165789 - A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations | Biotech Hunter | Biotech Hunter